Response and Result: The arguments tested showed that people highly value access to the best drugs and drug / plan choice, and that a government mandated program would unacceptably hurt R&D. In Massachusetts and Vermont our survey research proved critical in slowing the momentum among legislators for these flawed initiatives, and in Vermont the impact of the data may have contributed to killing the bill outright. In Wisconsin, we provided powerful, particularized data to the legislative leadership that guided both the campaign efforts of their colleagues and their messages in negotiating a compromise bill.